Filing Details
- Accession Number:
- 0000950170-24-075075
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-18 17:59:42
- Reporting Period:
- 2024-06-14
- Accepted Time:
- 2024-06-18 17:59:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1595097 | Corbus Pharmaceuticals Holdings Inc. | CRBP | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1451495 | F. Sean Moran | C/O Corbus Pharmaceuticals Holdings, Inc 500 River Ridge Drive Norwood MA 02062 | Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2024-06-14 | 1,567 | $30.00 | 50,172 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.0001 Per Share | Disposition | 2024-06-14 | 1,567 | $49.87 | 48,605 | No | 4 | S | Direct | |
| Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2024-06-14 | 7,788 | $4.26 | 56,393 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.0001 Per Share | Disposition | 2024-06-14 | 7,788 | $49.87 | 48,605 | No | 4 | S | Direct | |
| Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2024-06-17 | 6,730 | $14.10 | 55,335 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.0001 Per Share | Disposition | 2024-06-17 | 6,730 | $46.77 | 48,605 | No | 4 | S | Direct | |
| Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2024-06-18 | 1,958 | $30.00 | 50,563 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.0001 Per Share | Disposition | 2024-06-18 | 1,958 | $42.12 | 48,605 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Options to purchase common stock | Disposition | 2024-06-14 | 1,567 | $0.00 | 1,567 | $30.00 |
| Common Stock | Options to purchase common stock | Disposition | 2024-06-14 | 7,788 | $0.00 | 7,788 | $4.26 |
| Common Stock | Options to purchase common stock | Disposition | 2024-06-17 | 6,730 | $0.00 | 6,730 | $14.10 |
| Common Stock | Options to purchase common stock | Disposition | 2024-06-18 | 1,958 | $0.00 | 1,958 | $30.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,958 | 2024-10-22 | No | 4 | M | Direct | |
| 23,367 | 2024-02-13 | 2033-02-13 | No | 4 | M | Direct |
| 11,217 | 2023-02-01 | 2032-02-01 | No | 4 | M | Direct |
| 0 | 2024-10-22 | No | 4 | M | Direct |
Footnotes
- This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $52.525 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.88 to $49.47 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $43.59 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.
- The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.
- The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023.
Billionaire Hedge Funds
